A new daily pill form of the popular weight-loss drug Wegovy has received approval for use in the UK, potentially offering a more convenient treatment option for individuals living with obesity. Manufacturer Novo Nordisk states that the once-daily tablet could be preferable for some patients who are unable or unwilling to self-inject weekly with the existing GLP-1 medication. Furthermore, unlike the injectable version, the pills do not require refrigeration, simplifying storage.
The oral medication contains semaglutide, the same active ingredient as the injectable form. It works by mimicking a natural hormone called GLP-1, which helps to suppress appetite and slow digestion, promoting a feeling of fullness and reducing hunger. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a starting dose of 1.5 mg once daily, escalating to 4 mg, 9 mg, and 25 mg, with a minimum of one month at each dose level. Patients currently using the 2.4 mg semaglutide injection once weekly can transition directly to the 25 mg tablets once daily.
While the approval marks a significant step, the National Institute for Health and Care Excellence (NICE), which determines whether treatments are made available on the NHS, has not yet been formally approached by Novo Nordisk regarding the pill. However, NICE confirmed it is in "active dialogue" with the company. This suggests that while private prescriptions may become available sooner, NHS provision will depend on future assessments and negotiations.
The cost of Wegovy pills in the UK is not yet known. However, when the drug launched in the US, the manufacturer listed the starting dose of 1.5 mg at $149, which equates to approximately £110 per month. Olivier Picard, Chair of the National Pharmacy Association, described the approval as "significant" and expressed optimism that the pill format could lead to a long-term reduction in treatment costs. Pharmacies are now awaiting further guidance on when the treatment will become available for patients.
It is important to note that GLP-1 drugs, including Wegovy, are intended as part of a comprehensive weight management plan that includes a healthy diet and regular exercise. Health experts strongly caution against their use for short-term or cosmetic weight loss. Like all medications, there can be side effects, including nausea, diarrhoea, constipation, and vomiting. With approximately one-third of UK adults, over 16 million people, classified as obese, the introduction of a more accessible treatment option could have a considerable impact on public health strategies.
For UK households, the potential availability of a more convenient weight-loss medication could impact personal health spending, particularly if accessed privately. Businesses in the pharmacy sector may see increased demand for prescribing and dispensing services. The long-term economic implications for the NHS will depend on future NICE guidance and potential pricing agreements.
Source: Novo Nordisk, MHRA, National Pharmacy Association, NICE